Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
241 Clinical Updates found
Laboratory equipment for researchers
MSK Research Roundup at AACR 2023: Exciting Advances in Clinical, Translational, and Foundational Research

Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest clinical, translational, and foundational cancer research at ...
MSK Researchers Discover Targetable Mechanism Driving Late Cardiac Toxicity After DNA-Damaging Cancer Treatment
MSK Researchers Discover Targetable Mechanism Driving Late Cardiac Toxicity After DNA-Damaging Cancer Treatment

Memorial Sloan Kettering Cancer Center (MSK) researchers have discovered that innate immune signaling drives late cardiac toxicity after DNA-damaging c...
Medical Oncologist Mrinal Gounder, MD
Nirogacestat Improves Outcomes for Patients With Desmoid Tumors

Update: On November 27, 2023, the U.S. Food and Drug Administration approved nirogacestat (Ogsiveo™) for adults with desmoid tumors that cannot be...
physician-scientist Sarat Chandarlapaty, MD, PhD and colleague working in their MSK laboratory.
A Decade of MSK Research Laid Groundwork for Recent Approval of a Targeted Therapy for Metastatic Breast Cancer

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.
CAR T cell therapy
Allogeneic CAR T Cell Therapy for Multiple Myeloma Shows Promise

A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial (NCT04093596) published recently in Nature Medicine.
Photo of person walking in front of MSK Kids sign
Top Pediatric Cancer Advances at MSK Kids in 2022

Doctors at MSK Kids, the dedicated pediatric service at Memorial Sloan Kettering Cancer Center (MSK), pioneered many advances for pediatric patients in 2022.
Person in white lab coat using a pipette with a tiny test tube.
Top Cancer Research Advances at MSK in 2022

Read about some of the biggest scientific discoveries made by MSK researchers in 2022.
(Left to right) Sascha Roth, Luis Diaz, Imtiaz Hussain, Andrea Cercek, Avery Holmes, and Nisha Varughese.
Top Cancer Treatment Advances at MSK in 2022

Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.
Charlotte Ariyan
A Promising Neoadjuvant Combination Immunotherapy for Advanced Melanoma

Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University of Texas MD Anderson Cancer Center (MD Anderson).
Martin R. Weiser, MD
Updated Clinical Calculator Guides Treatment Plan for Rectal Cancer

Physicians at Memorial Sloan Kettering Cancer Center (MSK) have developed and validated clinical calculators to help patients estimate their likelihood of avoiding a recurrence after treatment for colorectal cancer.